ClinConnect ClinConnect Logo
Search / Trial NCT03463772

IVM Versus Standard IVF in Infertile Patients Diagnosed With PCOS

Launched by JIE QIAO · Mar 6, 2018

Trial Information

Current as of May 10, 2025

Unknown status

Keywords

In Vitro Maturation Polycystic Ovarian Syndrome Oocyte

ClinConnect Summary

A single center, randomized controlled clinical trial will enroll 350 couples with PCOS undergoing their first cycle of IVF. The participation in this study will be approximately 2 years with a total of 7 visits from the cycle beginning, pregnancy to delivery. On day 2 or day 3 following the onset of menstrual bleeding, eligible patients will be allocated to two groups at a ratio of 1:1- IVM protocol, and standard IVF protocol. All participants will be randomized through stratified block randomization according to the study sites.

Gender

FEMALE

Eligibility criteria

  • Inclusion Criteria:
  • 1. Infertile couples scheduled for their first IVF cycle.
  • 2. Women diagonosed with polycystic ovarian syndrome.
  • 3. Voluntary participation and informed consent obtained.
  • Exclusion Criteria:
  • 1. Couple with contraindication for IVF or ICSI.
  • 2. Couples receiving donor sperm or donor eggs.
  • 3. Couples with indications or have plan to receive PGD and PGS.
  • 4. Sperm analysis diagnosed as azoospermia;
  • 5. Either male partner or female partner with an abnormal chromosome karyotype (chromosome polymorphisms was not included).
  • 6. Women who have undergone unilateral ovariectomy.

About Jie Qiao

Jie Qiao is a leading clinical trial sponsor dedicated to advancing medical research and innovation through the development and execution of high-quality clinical studies. With a focus on patient-centered approaches and rigorous scientific methodologies, Jie Qiao collaborates with healthcare professionals and regulatory authorities to ensure the safety and efficacy of new therapies. Their commitment to ethical standards and transparency drives their mission to deliver meaningful advancements in healthcare, ultimately improving patient outcomes and contributing to the global medical community.

Locations

Beijing, Beijing, China

Patients applied

0 patients applied

Trial Officials

Jie Qiao

Study Director

Peking University Third Hospital

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials